Company news
Moonlake Immunotherapeutics (NASDAQ:MLTX) news
Moonlake Immunotherapeutics news releases on 6ix. Latest, Aug 10, 2026: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial…
Press releases & updates
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
August 10, 2026
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
June 23, 2026
MoonLake Immunotherapeutics Announces Proposed Public Offering
June 22, 2026
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
June 21, 2026
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
May 9, 2026
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
March 27, 2026
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
February 21, 2026
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
February 10, 2026
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
February 1, 2026
MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day
January 7, 2026
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
November 4, 2025
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
November 4, 2025
MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab
September 27, 2025
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
August 4, 2025
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
May 11, 2025
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
April 24, 2025
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
April 2, 2025
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
February 25, 2025
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
January 7, 2025
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
November 12, 2024
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
November 6, 2024
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
September 8, 2024
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
August 6, 2024
MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
June 9, 2024
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
May 15, 2024
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 6, 2024
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
April 9, 2024
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
April 9, 2024
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
March 9, 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
March 3, 2024
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
February 28, 2024
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
February 25, 2024
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 13, 2023
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
November 4, 2023
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
October 14, 2023
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
October 10, 2023
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
October 3, 2023
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
September 5, 2023
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 9, 2023
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
July 24, 2023
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
June 27, 2023
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
June 25, 2023
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
June 24, 2023
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
May 11, 2023
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
May 2, 2023
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
April 18, 2023
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
March 19, 2023
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
February 1, 2023
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis
December 13, 2022
MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update
November 13, 2022